COVID-19 Pandemic Linked to Reduced Short-Term Survival in Cancer Patients
Overview
A recent study published in JAMA Oncology reveals that cancer patients diagnosed during 2020 and 2021 experienced worse one-year survival rates compared to those diagnosed from 2015 to 2019. This decline in survival was observed across multiple cancer types and stages, likely influenced by pandemic-related healthcare disruptions.
Background
The COVID-19 pandemic caused significant interruptions in cancer screening, diagnosis, and treatment services due to overwhelmed healthcare systems. While overall cancer death rates in the U.S. continued to decline during the pandemic, concerns arose about the impact of delayed care on newly diagnosed patients. This study is the first to specifically evaluate short-term survival outcomes in cancer patients diagnosed during the pandemic, excluding deaths primarily caused by COVID-19 infection.
Data Highlights
Metric
2015-2019
2020-2021
Number of new cancer diagnoses
—
Over 1 million
One-year survival rate (early-stage cancers)
Above 96%
Just over 96%
One-year survival rate (late-stage cancers)
Above 74%
Just over 74%
Excess deaths within one year
—
Approximately 17,400 more than expected
Key Findings
Patients diagnosed with cancer in 2020-2021 had worse one-year survival compared to those diagnosed in 2015-2019.
Survival declines were observed across all cancer sites and stages, notably in colorectal, prostate, and pancreatic cancers.
The study excluded deaths primarily attributed to COVID-19 to isolate effects of healthcare disruptions.
More than 96% of early-stage and over 74% of late-stage cancer patients diagnosed during the pandemic survived beyond one year, slightly lower than expected.
Estimated 17,400 excess deaths occurred within one year among patients diagnosed during the pandemic period.
Healthcare system disruptions, including postponed screenings and delayed treatments, are probable contributors to reduced survival.
Clinical Implications
Clinicians should be aware that pandemic-related delays in cancer diagnosis and treatment may have negatively impacted short-term patient survival. Efforts to maintain timely cancer screening and treatment access during healthcare crises are critical to prevent excess mortality. Continued monitoring of long-term outcomes is necessary to understand the full impact and guide future preparedness.
Conclusion
The COVID-19 pandemic has been associated with a measurable decline in short-term survival among newly diagnosed cancer patients, likely due to healthcare disruptions. Addressing these challenges is essential to mitigate adverse outcomes in ongoing and future public health emergencies.
References
AP/JAMA Oncology/2023 -- Research Examines the Effects of the COVID-19 Pandemic on Cancer Patient Survival Rates
